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Abstract 
Background: The hyperinsulinemia of obesity is a function of both increased pancreatic insulin secretion and 
decreased insulin clearance, and contributes to cardiovascular risk. Whilst weight loss is known to enhance insulin 
clearance, there is a paucity of data concerning the underlying mechanisms. This study was conducted to examine 
the inter-relationships between changes in sympathetic nervous system (SNS) activity, vascular function and insulin 
clearance during a weight loss program.
Methods: Seventeen non-smoking, un-medicated individuals aged 55 ± 1 years (mean ± SEM), body mass index 
(BMI) 33.9 ± 1.7 kg/m2, underwent a 4-month hypocaloric diet (HCD), using a modified Dietary Approaches to Stop 
Hypertension diet, whilst seventeen age- and BMI-matched subjects acted as controls. Insulin sensitivity and insulin 
clearance were assessed via euglycemic hyperinsulinemic clamp (exogenous insulin clearance); hepatic insulin extrac-
tion was calculated as fasting C-peptide to insulin ratio (endogenous insulin clearance); SNS activity was quantified by 
microneurographic nerve recordings of muscle sympathetic nerve activity (MSNA) and whole-body norepinephrine 
kinetics; and vascular function by calf venous occlusion plethysmography and finger arterial tonometry.
Results: Weight loss averaged −8.3 ± 0.6 % of body weight in the HCD group and was accompanied by increased 
clamp-derived glucose utilization (by 20 ± 9 %, P = 0.04) and exogenous insulin clearance (by 12 ± 5 %, P = 0.02). 
Hepatic insulin extraction increased from 6.3 ± 0.8 to 7.1 ± 0.9 (P = 0.09). Arterial norepinephrine concentration 
decreased by −12 ± 5 %, whole-body norepinephrine spillover rate by −14 ± 8 %, and MSNA by −9 ± 5 bursts per 
100 heartbeats in the HCD group (P all >0.05 versus control group). Step-wise regression analysis revealed a bidirec-
tional relationship between enhanced exogenous insulin clearance post weight loss and reduction in calf vascular 
resistance (r = −0.63, P = 0.01) which explained 40 % of the variance. Increase in hepatic insulin extraction was 
predicted by enhanced finger reactive hyperaemic response (P = 0.006) and improvement in oral glucose tolerance 
(P = 0.002) which together explained 64 % of the variance.
Conclusions: Insulin clearance is independently and reciprocally associated with changes in vascular function during 
weight loss intervention.
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Background
Hyperinsulinemia is a common characteristic of obesity 
and has been prospectively linked to the development of 
cardiovascular morbidity and mortality [1, 2]. The eleva-
tion in peripheral insulin concentration under both fast-
ing and stimulated conditions has been attributed to the 
combined effects of increased pancreatic insulin secre-
tion and reduced insulin clearance, physiological pro-
cesses that are a function of the prevailing level of insulin 
resistance [3–5]. Indeed, longitudinal studies using a 
fat fed canine model [6] and intentional weight gain in 
healthy humans [7] indicate that reduced insulin clear-
ance is an early adaptive phenomenon that may oper-
ate to preserve pancreatic β-cell function from excessive 
demand in the insulin resistant state. Within obese pop-
ulations, upper body fat distribution, increased liver fat 
content, hypertension, hyperglycemia and dyslipidemia 
(known collectively as the metabolic syndrome), have 
been shown to confer lower insulin clearance [5, 8–12]. 
Despite its importance in the metabolism of insulin and 
its potential role in the aetiology of cardiovascular dis-
ease and diabetes [13], relatively little is known concern-
ing the mechanisms responsible for impaired insulin 
clearance in obesity and for the recognized benefits of 
weight loss in this regard [14, 15].
The liver and the kidneys are the principle sites of 
insulin clearance from the circulation, accounting for 
approximately 60 and 25  % respectively of total clear-
ance at physiological insulin levels [16], although other 
insulin sensitive tissues such as muscle and adipose tis-
sue also participate to a lesser extent. Insulin uptake and 
degradation involves several steps, including binding to 
the insulin membrane receptor, cellular internalization 
and enzymatic degradation [17]. Our group has recently 
demonstrated inverse associations between resting sym-
pathetic nervous system (SNS) activity, quantified as 
arterial norepinephrine concentration and whole-body 
norepinephrine spillover rate, peripheral arterial stiffness 
and insulin clearance in obese individuals with meta-
bolic syndrome [18]. This concurs with an earlier study 
which showed that acute infusion of the α1-adrenergic 
agonist phenylephrine during hyperinsulinemic eug-
lycemic clamp, decreased insulin clearance by 20  % in 
healthy volunteers [19]. Putative mechanisms by which 
catecholamine stimulation may adversely impact on insu-
lin clearance include hemodynamic alterations such as 
enhanced vasoconstrictor tone and microvascular rare-
faction that promote insulin resistance [20, 21], reduction 
in hepatic or renal blood flow [22, 23] and modulation of 
insulin receptor numbers and/or insulin binding affinity 
[24, 25]. Whilst the reciprocal interplay between insulin 
resistance, hyperinsulinemia and SNS activation has been 
long appreciated [21, 26], there is a paucity of knowledge 
regarding their interrelationship to insulin clearance, 
particularly in the context of weight loss which is known 
to elicit both sympathoinhibition and enhanced insulin 
sensitivity.
The aims of the present study were (1) to examine the 
effects of weight loss induced by hypocaloric diet (HCD) 
on insulin clearance, SNS activity and vascular func-
tion and (2) to delineate the pathophysiological drivers 
of improvement in insulin clearance following lifestyle 
intervention. We hypothesized that reduction in SNS 
activity would predict improvement in insulin clearance.
Methods
Subjects
Seventeen overweight and obese subjects were recruited 
through newspaper advertisements to participate in 
a weight loss trial (NCT01771042). They were com-
pared with age- and BMI-matched controls (n  =  17) 
who had been studied previously in our laboratory 
(NCT00408850). Entry criteria and study methodology 
were identical in the two studies. Subjects were non-
smokers, aged 45–65  years, with a stable body weight 
(±1  kg) in the previous 6  months and were not taking 
medications that could affect study parameters (e.g. oral 
hypoglycemics, cholesterol-lowering, anti-hypertensive, 
anti-depressant and hormone replacement therapies). 
Females were post-menopausal. Exclusion criteria com-
prised history of cardiovascular, cerebrovascular, renal, 
liver, or thyroid diseases and use of continuous posi-
tive airway pressure treatment. Screening tests included 
physical examination, electrocardiogram, biochemical 
tests, medical and dietary history, and measurement of 
supine resting blood pressure as the average of five read-
ings after 5  min rest using a Dinamap monitor (Model 
1846SX, Critikon Inc, Tampa, FL, USA). Clinical inves-
tigations were performed at baseline and after 16-weeks 
HCD or no treatment (controls). The project was 
approved by the Alfred Hospital Human Research Ethics 
Committee and written informed consent was obtained 
from each participant.
Dietary intervention
Habitual dietary intake was assessed by 4-day prospec-
tive diet records using Australian food composition 
tables (Foodworks 7 Professional, Xyris Software, Ken-
more Hills Qld 4069). Subjects were prescribed HCD at 
25  % energy deficit using a modified Dietary Approach 
to Stop Hypertension (DASH) eating plan [27], with 
higher protein and lower carbohydrate content (25  % 
protein, 30  % fat and 45  % carbohydrate) to maximize 
fat loss [28]. The DASH eating pattern has an empha-
sis on fruits and vegetables, low-fat dairy, wholegrain 
cereals, legumes and nuts, lean meats, poultry and fish. 
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Randomized controlled trials have established that this 
dietary pattern lowers blood pressure and lipid levels 
and favourably influences metabolic syndrome compo-
nents when used as the background diet during weight 
reduction [27, 29, 30]. Subjects were provided with 
written dietary instructions, 14-day menu plans and 
recipes, and prepared food in their home environment. 
They attended fortnightly for body weight measure-
ment and dietary counselling with the study dietician. 
With regards to exercise they were instructed to walk 
briskly for 30  min, at least 5  days per week, in accord-
ance with the American Diabetes Association Position 
Statement [31] and this was monitored by 7-day pedom-
etry. Control subjects were told to maintain their usual 
eating and exercise habits. Dietary intake was monitored 
by prospective 4-days diet records and 24-h urinaly-
sis (collected on the day prior to SNS tests) to quantify 
sodium, potassium, urea and creatinine excretion. Clini-
cal testing was performed on two separate mornings a 
week apart. Subjects attended at 8 am after an overnight 
fast and having abstained from alcohol and heavy exer-
cise for 36 h and caffeine for 18 h. All experiments were 
performed in the supine position in a temperature con-
trolled (22 °C) research room.
Glucose metabolism and insulin clearance
Participants underwent a standard 75-g oral glucose tol-
erance test (OGTT, Glucaid, Fronine PTY, LTD, Taren 
Point, NSW 2229, Australia) with 30-min blood sam-
pling. The Matsuda insulin sensitivity index (ISI) was 
calculated as a measure of insulin sensitivity to endog-
enously produced insulin [32]. On a separate day, the 
euglycemic hyperinsulinemic clamp was initiated by an 
intravenous bolus injection of insulin (9 mU/kg; Actrapid 
100 IU/ml Novo Nordisk, Gentofte, Denmark), followed 
by a constant infusion rate of 40 mU m2 min−1. Arteri-
alized blood glucose was clamped at 5.0 mmol/L by the 
variable infusion of 25  % glucose (Baxter, Toongabbie, 
Australia) and measured every 5-min using an ABL8XX 
glucose auto-analyzer (Radiometer, Copenhagen, Den-
mark). The mean glucose infusion rate between 90 and 
120  min was used to calculate whole-body glucose uti-
lization [M value, expressed as mg per min and mg per 
kg fat free mass (FFM) per min] and adjusted for steady-
state insulin (M/I value). Fasting and steady-state C-pep-
tide concentrations were measured to verify suppression 
of endogenous insulin secretion.
Whole-body exogenous insulin clearance was calcu-
lated by dividing the insulin infusion rate by the mean 
steady-state plasma insulin concentration (average of 
measurements at 90, 100, 110 and 120 min) with correc-
tion for changes in residual endogenous insulin secretion 
according to the formula [33]:
where SSi represents steady-state plasma insulin levels 
during the clamp (mU/L), Bi represents basal or fasting 
plasma insulin (mU/L) and SSCP and BCP are steady-state 
and basal C-peptide concentrations (pmol/L) respec-
tively. Hepatic insulin extraction (endogenous insulin 
clearance) was calculated as the ratio of fasting C-peptide 
to fasting insulin concentration (both values expressed as 
pmol/L). This is based on the assumption that C-peptide 
is secreted equimolarly with insulin but is not subjected 
to hepatic first-pass metabolism.
Body weight was measured in light indoor clothes with-
out shoes using a digital scale. Body composition was 
determined by whole-body dual-energy X-ray absorptiom-
etry (DEXA, GE-LUNAR Prodigy Advance PA+130510, 
GE Medical Systems, Lunar, Madison, W1, USA).
Norepinephrine kinetics
Fasting norepinephrine kinetics were determined on the 
same morning and prior to the OGTT. After cannula-
tion of an antecubital vein and the brachial artery, fast-
ing venous blood samples were obtained for biochemical 
measurements. Radioisotope dilution methodology was 
then used to quantify the rate at which norepinephrine 
released from sympathetic nerve endings enters the cen-
tral plasma compartment (whole-body norepinephrine 
‘spillover’ rate) [34]. This technique involves the intrave-
nous infusion of [3H]-norepinephrine and measurement 
of norepinephrine specific activity and endogenous nor-
epinephrine in arterial blood, sampled from the brachial 
artery, under steady-state conditions. After a priming 
bolus of 1.81 μCi of 1-[ring-2,5,6-3H]-norepinephrine 
(Perkin-Elmer, Waltham, MA, USA; specific activity, 
10–30μCi/mmol), an infusion was commenced at 0.18 
μCi  min−1, with arterial blood sampling 30  min after 
infusion commencement. The following calculations 
were performed:
After completion of arterial blood sampling, subjects 
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that high specific activity [3H]-norepinephrine has no 
physiological effects at the doses used [34].
Muscle sympathetic nerve activity
Resting multi-unit muscle sympathetic nerve activity 
(MSNA) activity was measured via a tungsten microelec-
trode inserted into a muscle nerve fascicle of the right 
peroneal nerve at the fibular head. Once an acceptable 
nerve-recording site was obtained via visual and acous-
tic identification of spontaneous sympathetic bursts, 
resting measurements were recorded over 15  min. The 
nerve signal was amplified (×50,000), filtered (bandpass, 
700–2000 Hz) and integrated. Continuous electrocardio-
graphic and MSNA recordings were digitised with a sam-
pling frequency of 1000 Hz (PowerLab recording system, 
model ML785/8SP, AD Instruments). MSNA was manu-
ally analysed and expressed as burst frequency (bursts/
min) and burst incidence (bursts/100 heartbeats), aver-
aged over 15 min.
Cardiovascular parameters
Resting cardiac baroreflex sensitivity was estimated 
using the sequence method. This procedure identifies 
the spontaneous sequences of three or more consecu-
tive heartbeats during which intra-arterial systolic blood 
pressure increased and cardiac interval lengthened (type 
1 sequences) or systolic blood pressure decreased and 
cardiac interval shortened (type 2 sequences), with a lag 
of one beat. The slope of the regression line between car-
diac interval and intra-arterial systolic blood pressure 
values was calculated for each validated sequence (when 
r > 0.85). Individual slopes were averaged over a 15 min 
recording period.
Cardiac output was quantified by transthoracic Dop-
pler echocardiography (Vivid 7 GE Vingmed, GE 
Healthcare) from the left ventricular outflow tract 
cross-sectional diameter and the velocity time integral 
measurements.
Calf blood flow measurements were obtained in the left 
leg by venous occlusion plethysmography (D.E.Hokansen, 
Bellevue, WA, USA). Strain gauges were attached around 
the thickest part of the calf and the measured leg was 
supported 10 cm above heart level to empty the venous 
system. Twelve consecutive readings were averaged and 
expressed as mL per min per 100 g of tissue. Calf vascu-
lar resistance was calculated as mean arterial pressure 
(MAP) divided by calf blood flow. Measurements were 
made in the fasting state and every 30 min during OGTT 
to quantify the vasodilatory response to endogenous 
insulin.
Endothelial function was evaluated non-invasively in 
the index finger of the non-dominant hand by the Endo-
PAT 2000 device (Itamar Medical Ltd, Caesarea, Israel). 
A beat-to-beat plethysmographic recording of the arte-
rial pulse-wave was obtained over 5  min of supine rest. 
Brachial arterial occlusion was then induced by inflating 
an upper arm cuff to supra-systolic pressure (60 mmHg 
above systolic pressure) for 5 min, and released to elicit 
reactive flow-mediated hyperaemia. Pulse amplitude 
responses to hyperaemia were calculated from the hyper-
aemic fingertip as the ratio of the post deflation pulse 
amplitude between 90 and 120  s to the baseline pulse 
amplitude and adjusted for the corresponding ratio in the 
contralateral control hand (PAT ratio) [35].
Laboratory analyses
Plasma glucose and lipid profile were measured on a 
commercial analytical system (Architect C18000  ana-
lyzer, Abbott Laboratories, Illinois, USA). High sensitivity 
C-reactive protein (hs-CRP was quantified by immuno-
turbidimetric assay, insulin and leptin by radio-immuno 
assay (Linco Research, Inc, Missouri, USA), C-peptide 
by chemiluminescent immunoassay (ADVIA Centaur, 
Siemens Healthcare Diagnostics, Tarrytown, NY, USA) 
and non-esterified fatty acids (NEFA) by enzymatic col-
orimetric method (Wako Pure Chemical Industries, 
Ltd, Osaka, Japan). Plasma norepinephrine was assayed 
by high performance liquid chromatography with elec-
trochemical detection, following extraction by alumina 
adsorption. [3H]-norepinephrine was assayed by liq-
uid scintillation chromatography and corrected for loss 
during extraction using recoveries of internal standard. 
Intra-assay CVs in our laboratory are 1.3  % for norepi-
nephrine and 2.3 % for [3H]-norepinephrine; inter-assay 
CVs are 3.8 and 4.5 %, respectively.
Statistical analyses
Statistical analysis was performed using SigmaStat Ver-
sion 3.5 (Systat Software Inc, Point Richmond, CA, USA). 
Data are presented as the mean ± SEM. Baseline parame-
ters in the two study groups were compared by un-paired 
t-tests and Mann–Whitney rank sum test. Two-way 
repeat measures ANOVA was used to test for group 
effects, time effects and group × time interactions, with 
the Holm-Sidak test for multiple post hoc comparisons. 
Non-parametric data were log transformed. Post-inter-
vention changes in study parameters (Δ) were compared 
by un-paired t test or Mann–Whitney test as appropriate. 
Sub-group analysis by baseline insulin status, was per-
formed using a cut-point of insulin area under the curve 
during OGTT (AUC0–120) of 8000 mU/L per minute, to 
categorize subjects as hyperinsulinemic or normoinsu-
linemic [36]. Univariate associations between change in 
insulin clearance and other variables were assessed using 
Pearson’s correlations. Forward stepwise linear regres-
sion analysis, adjusted for age and change in body weight, 
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was performed to identify the independent predictors of 
change in insulin clearance in the HCD group. Variables 
with P values <0.10 in univariate analyses were entered 
into the regression model. Statistical significance was 
accepted at the P < 0.05 (two-tailed) level.
Results
Subjects
Baseline demographic, clinical and dietary character-
istics of study participants are presented in Table  1. 
Control and HCD groups were well matched for age, 
anthropometrics, glucose metabolism and blood pres-
sure. Body weight and total body fat mass decreased by 
−8.3 ± 0.6 % (range −3.6 to −11.6 %) and −6.2 ± 0.7 kg 
respectively and plasma leptin by −8.5 ±  2.1  ng/mL in 
the HCD group (all P  <  0.001 versus control group, 
Table 2). Based on 4-day diet records, energy deficit aver-
aged −543  ±  100  kcal/day, carbohydrate and saturated 
fat intake decreased by −6.3 ± 1.4 % and −2.9 ± 0.8 % 
(−12 ± 3 g/day) of energy respectively, and protein intake 
increased by 7.5 ±  1.2 % of energy (all P ≤  0.001). Uri-
nary sodium excretion decreased by −42 ± 18 mmol/day 
in the HCD group and −5 ± 13 mmol/day in the control 
group (P = 0.11), whereas potassium and urea excretion 
were unchanged. Pedometry records showed an incre-
ment of 1419 ± 561 steps/day in the HCD (P = 0.03).
Cholesterol profile improved significantly after weight 
loss: plasma LDL-cholesterol and triglyceride concentra-
tions fell, whilst HDL-cholesterol increased compared to 
control subjects (all P < 0.05, Table 2). The inflammatory 
marker hs-CRP decreased significantly only in the HCD 
group.
Glucose metabolism and insulin clearance
Fasting glucose and insulin, and the glucose and insu-
lin areas under the curve between time 0 and 120  min 
(AUC0–120) during the OGTT, decreased significantly in 
the HCD group (P all ≤0.01) and there was a commensu-
rate reduction in HOMA-IR and an increase in Matsuda 
ISI (P both <0.001)(Fig. 1a, b). Clamp derived glucose uti-
lization increased by an average of 20 ± 9 % in the HCD 
group (P  =  0.02 versus control group) (Fig.  1c). Fast-
ing C-peptide to insulin ratio increased from 6.3 ±  0.8 
at baseline to 7.1  ±  0.9 post-weight loss in the HCD 
group (P  =  0.09) (Fig.  1d). Exogenous insulin clear-
ance increased from 352 ±  14 to 393 ±  21 mL/m2/min 
(P = 0.02) (Fig. 1e), representing and average increment 
of 12 ± 5 %. There were no changes in glucose or insulin 
parameters in the control group.
Sympathetic nervous system activity
Figure  2 illustrates changes in MSNA burst incidence 
and norepinephrine kinetics in relation to changes in 
body weight and insulin status in the study groups. 
Arterial norepinephrine concentration and calculated 
whole-body norepinephrine spillover rate decreased by 
−12 ± 5 % and −14 ± 8 % respectively in the HCD group, 
which did not differ significantly from changes in the 
control group. Satisfactory paired MSNA measurements 
were obtained in 10 control and 13 HCD subjects. MSNA 
decreased by −7 ± 3 bursts/min and −9 ± 5 bursts per 
100  hb in the HCD, but this did not differ significantly 
from changes in the control group. Sub-group analy-
ses by baseline insulin status (hyperinsulinemic: insulin 
AUC0–120 10,394 ± 694 mU/L per min, n = 10; normo-
insulinemic: insulin AUC0–120 5469  ±  501 mu/L per 
min, n = 7), showed that significant sympathoinhibition 
Table 1 Demographic, clinical and  dietary variables 
of study participants
BP blood pressure, HOMA-IR homeostasis model assessment of insulin resistance, 
M steady state glucose utilization during euglycemic hyperinsulinemic clamp 
(mg per kg fat free mass per minute), MetS metabolic syndrome components 






Age (years) 56 ± 1 55 ± 1 0.87
Gender (M/F) 10/7 7/10 0.49
Number of MetS components 2.7 ± 0.3 2.5 ± 0.3 0.68
Clinical parameters
 Body weight (kg) 97.8 ± 4.0 98.6 ± 4.1 0.89
 Body mass index (kg/m2) 32.8 ± 0.9 33.9 ± 1.7 0.85
 Waist circumference (cm) 106.1 ± 2.3 107.8 ± 2.8 0.63
 Waist to hip ratio 0.91 ± 0.02 0.91 ± 0.02 0.96
 Fasting glucose (mmol/L) 5.8 ± 0.1 6.1 ± 0.2 0.24
 2-h glucose (mmol/L) 9.6 ± 0.7 10.4 ± 0.7 0.44
 Fasting insulin (mU/L) 17.7 ± 1.6 18.0 ± 1.4 0.88
 HOMA-IR 4.8 ± 0.4 4.9 ± 0.5 0.90
 M (mg kg FFM min−1) 9.49 ± 0.82 10.24 ± 0.93 0.55
 Insulin clearance (mL m2 min−1) 382 ± 20 352 ± 14 0.23
 Triglycerides (mmol/L) 1.5 ± 0.1 1.7 ± 0.2 0.77
 HDL-cholesterol (mmol/L) 1.29 ± 0.07 1.20 ± 0.06 0.44
 LDL-cholesterol (mmol/L) 3.4 ± 0.1 3.9 ± 0.2 0.07
Clinic systolic BP (mmHg) 127 ± 4 121 ± 2 0.22
 Clinic diastolic BP (mmHg) 72 ± 2 69 ± 2 0.27
 Clinic heart rate (bpm) 62 ± 2 62 ± 2 0.92
 7-day pedometry (steps per day) 8021 ± 724 8824 ± 1100 0.68
Habitual dietary intake
 Energy (kcal/day) 2081 ± 158 2067 ± 86 0.69
 Fat (% energy) 34 ± 2 36 ± 1 0.32
 Saturated fat (% energy) 14 ± 1 15 ± 1 0.46
 Protein (% energy) 19 ± 1 18 ± 1 0.83
 Carbohydrate (% energy) 44 ± 2 41 ± 2 0.28
 Alcohol (% energy) 2 ± 1 2 ± 1 0.74
 24-h urinary sodium (mmol/day) 155 ± 20 157 ± 14 0.58
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Table 2 Anthropometric, metabolic and cardiovascular parameters at baseline and post interventions
BRS baroreflex sensitivity, CRP C-reactive protein, MAP mean arterial pressure, NEFA non-esterified fatty acids, PAT peripheral arterial tonometry
* P < 0.05, ** P < 0.01 and *** P < 0.001 versus Baseline; † P < 0.05 and ‡P ≤ 0.01 versus Control Group
Variables Control HCD Group × time 
interaction (P)
Baseline Week 16 Baseline Week 16
Anthropometric
 Body weight (kg) 97.8 ± 4.0 98.2 ± 4.2 98.6 ± 4.1 90.4 ± 4.0*** <0.001
 Δ 0.4 ± 0.4 −8.1 ± 0.6‡
 Body mass index (kg/m2) 32.8 ± 0.9 32.9 ± 1.0 33.9 ± 1.7 31.2 ± 1.7*** <0.001
 Δ 0.2 ± 0.2 −2.7 ± 0.2‡
 Waist circumference (cm) 106.1 ± 2.3 106.5 ± 2.2 107.8 ± 2.8 100.3 ± 2.8*** <0.001
 Δ 0.4 ± 0.4 −7.5 ± 0.9‡
 Waist to hip ratio 0.91 ± 0.02 0.92 ± 0.02 0.91 ± 0.02 0.89 ± 0.01*** 0.001
 Δ 0.0 ± 0.0 −0.03 ± 0.01‡
 Total body fat mass (kg) 38.0 ± 2.9 38.0 ± 3.0 42.0 ± 2.7 35.8 ± 3.1*** <0.001
 Δ 0.1 ± 0.3 −6.2 ± 0.7‡
Metabolic and biochemical
 Fasting glucose (mmol/L) 5.8 ± 0.1 5.9 ± 0.1 6.1 ± 0.2 5.8 ± 0.1** 0.03
 Δ 0.0 ± 0.1 −0.3 ± 0.1†
 Fasting insulin (mU/L) 18.8 ± 1.7 20.4 ± 1.6* 18.0 ± 1.4 13.8 ± 1.2***‡ <0.001
 Δ 1.7 ± 0.9 −4.2 ± 0.7‡
 Triglycerides (mmol/L) 1.5 ± 0.1 1.4 ± 0.1 1.7 ± 0.2 1.1 ± 0.1*** 0.02
 Δ −0.1 ± 0.1 −0.6 ± 0.2†
 HDL-cholesterol (mmol/L) 1.29 ± 0.07 1.20 ± 0.06* 1.21 ± 0.05 1.25 ± 0.07 0.02
 Δ −0.09 ± 0.04 0.04 ± 0.03†
 LDL-cholesterol (mmol/L) 3.4 ± 0.1 3.4 ± 0.2 3.8 ± 0.2 3.5 ± 0.2** 0.02
 Δ 0.0 ± 0.1 −0.3 ± 0.1†
 NEFA (mEq/L) 0.53 ± 0.04 0.51 ± 0.04 0.57 ± 0.05 0.55 ± 0.04 0.93
 Δ −0.02 ± 0.03 −0.02 ± 0.04
 Leptin (ng/mL) 18.7 ± 4.6 19.1 ± 3.6 21.6 ± 4.7 13.1 ± 3.4*** <0.001
 Δ 0.4 ± 1.6 −8.5 ± 2.1‡
 High sensitivity CRP (mg/L) 3.3 ± 0.8 3.5 ± 0.9 3.2 ± 0.6 2.2 ± 0.4* 0.12
 Δ 0.2 ± 0.6 −0.9 ± 0.3†
 Creatinine clearance (mL/min) 150 ± 11 147 ± 9 140 ± 10 118 ± 7**† 0.06
 Δ −3 ± 6 −22 ± 10
Cardiovascular
 Clinic MAP (mmHg) 92 ± 3 95 ± 3 89 ± 2 86 ± 2* 0.007
 Δ 3 ± 2 −3 ± 1‡
 Clinic heart rate (bpm) 62 ± 2 61 ± 2 62 ± 2 59 ± 2* 0.41
 Δ −2 ± 1 −3 ± 1
 Cardiac BRS (ms/mmHg) 15.7 ± 2.2 15.7 ± 1.9 18.0 ± 2.6 23.7 ± 2.9*† 0.16
 Δ 0.0 ± 2.2 5.8 ± 2.3
 Calf vascular resistance (units) 53.0 ± 6.7 57.4 ± 4.4 51.3 ± 4.9 47.1 ± 3.3 0.18
 Δ 4.4 ± 4.6 −4.2 ± 3.9
 Finger reactive hyperaemic index 2.35 ± 0.15 2.42 ± 0.16 2.38 ± 0.19 2.26 ± 0.15 0.44
 Δ 0.07 ± 0.13 −0.12 ± 0.20
 PAT ratio 0.68 ± 0.09 0.67 ± 0.09 0.67 ± 0.10 0.62 ± 0.09 0.77
 Δ −0.01 ± 0.10 −0.05 ± 0.11
 Cardiac output (L/min) 5.3 ± 0.3 5.6 ± 0.4 5.5 ± 0.4 5.4 ± 0.4 0.30
 Δ 0.3 ± 0.2 −0.1 ± 0.2
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Fig. 1 Changes in insulin sensitivity and insulin clearance in control and hypocaloric diet (HCD) groups (week 16 minus baseline measurements). 
a Homeostasis model assessment of insulin resistance (HOMA-IR): group × time interaction, P < 0.001. b Matsuda insulin sensitivity index (ISI): 
group × time interaction, P < 0.001. c Steady state glucose utilization during euglycemic clamp (M): group × time interaction, P = 0.02. d Fasting 
C-peptide to insulin ratio: group × time interaction, P = 0.06. e Insulin clearance: group × time interaction, P = 0.03. *P < 0.05 and ***P < 0.001 
versus control group
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(reduction in whole-body norepinephrine spillover rate) 
was only attained in hyperinsulinemic subjects following 
HCD, despite similar weight loss in the two sub-groups 
(Fig. 2f ).
Cardiovascular parameters
Cardiovascular parameters are presented in Table  2. 
Clinic MAP was reduced and spontaneous cardiac 
baroreflex sensitivity was enhanced following weight loss 
Fig. 2 Change in sympathetic nervous system parameters in relation to change in body weight and insulin status in control and hypocaloric diet 
(HCD) groups (week 16 minus baseline measurements). HCD sub-groups are indicated by the hashed bars and include hyperinsulinemic (Hyper, 
n = 10) and normo-insulinemic (Normo, n = 7) subjects. a Body weight. b Insulin area under the curve during oral glucose tolerance test (AUC0–120). 
c Muscle sympathetic nerve activity (MSNA) burst incidence. d Arterial plasma norepinephrine (NE) concentration. e Norepinephrine plasma clear-
ance. f Whole-body norepinephrine spillover rate. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control group
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(P both <0.05 versus control group). Cardiac output, fin-
ger reactive hyperaemic response and PAT ratio were not 
significantly altered with weight loss. Fasting calf vascu-
lar resistance decreased non-significantly after weight 
loss (P  =  0.17 versus control) and there was a greater 
vasodilatory response to endogenous insulin during the 
OGTT in HCD, but not the control group (Fig. 3). Base-
line insulin status did not modify changes in cardiovascu-
lar parameters following HCD.
Correlation and regression analyses
Post weight loss change in exogenous insulin clearance 
(n  =  17) correlated positively with changes in HDL-
cholesterol (r = 0.53 P = 0.03), cardiac output (r = 0.44, 
P  =  0.08), M (r  =  0.45, P  =  0.07) and inversely with 
changes in fasting calf vascular resistance (r  =  −0.63 
P  =  0.007), calf vascular resistance during OGTT 
(AUC0-120) (r = −0.58, P = 0.01) and hs-CRP (r = −0.49, 
P  =  0.05) (Fig.  4). Post weight loss change in fasting 
C-peptide to insulin ratio correlated positively with 
changes in Matsuda ISI (r =  0.52, P =  0.03) and finger 
reactive hyperaemic response (r  =  0.49, P  =  0.04) and 
inversely with changes in glucose AUC0-120 (r = −0.61, 
P = 0.009) and HOMA-IR (r = −0.53, P = 0.03) (Fig. 4). 
Changes in anthropometrics, sympathetic neural param-
eters (arterial norepinephrine concentration, norepi-
nephrine spillover rate and MSNA), creatinine clearance, 
and urinary sodium and potassium excretion did not 
correlate with change in exogenous insulin clearance or 
hepatic insulin extraction.
Stepwise regression analyses are summarized in Table 3. 
Improvement in exogenous insulin clearance after weight 
loss intervention was independently predicted by reduc-
tion in fasting calf vascular resistance and increase in 
HDL-cholesterol, which together explained 55  % of the 
variance. Improvement in hepatic insulin extraction after 
weight loss was independently predicted by enhanced 
glucose tolerance (reduced glucose AUC0–120) and finger 
reactive hyperaemic response, which together explained 
64 % of the variance. In turn, change in fasting calf vas-
cular resistance was independently predicted by improve-
ment in insulin clearance and reduction in hs-CRP; 
enhancement in vasodilatory response during OGTT was 
predicted by improvement in insulin sensitivity; whilst 
change in the reactive hyperaemic response was inversely 
and independently predicted by change in MAP. Regard-
ing SNS parameters, change in arterial norepinephrine 
concentration post weight loss was the strongest inde-
pendent predictor of change in MAP, whilst reduction in 
MSNA was a function of improved baroreflex sensitivity 
(Table 3).
Discussion
Hyperinsulinemia is considered to be a core component 
in the pathophysiology of obesity-related comorbidi-
ties [1, 2]. The focus of this study was insulin clearance, 
a key determinant of fasting and postprandial plasma 
insulin levels, which is known to be reduced in obesity 
particularly when features of the metabolic syndrome 
are present [5]. We simultaneously evaluated changes in 
sympathetic neural parameters, vascular and metabolic 
function, and anthropometrics following a HCD in order 
to ascertain the drivers of improvement in insulin clear-
ance during lifestyle intervention. There are three main 
Fig. 3 Calf vascular resistance during 75-g oral glucose tolerance test in a control and b HCD groups. *P < 0.05 versus baseline. Change in the area 
under the curve (AUC0–120) averaged 927 ± 555 units per min and −712 ± 526 units per min in control and HCD groups, respectively (P = 0.045)
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findings from our study. First, that weight loss of −8.3 % 
of baseline body weight elicited significant improve-
ment in whole-body insulin clearance (by 12  %) and a 
non-significant increase in fasting hepatic insulin extrac-
tion (by 17 %) within our cohort. Second, that although 
vascular responses to weight loss were heterogeneous, 
Fig. 4 Univariate correlates of change in whole-body insulin clearance and hepatic insulin extraction (fasting C-peptide to insulin ratio) in the 
HCD group (n = 17). a Change in fasting calf vascular resistance (r = −0.63, 0.007). b Change in steady state glucose utilization during euglycemic 
hyperinsulinemic clamp (M) (r = 0.45, P = 0.07). c Change in plasma HDL-cholesterol concentration (r = 0.53, P = 0.03). d Change in finger reactive 
hyperaemic index (r = 0.49 P = 0.04). e Change in Matsuda insulin sensitivity index (ISI) (r = 0.52, P = 0.03). f Change in glucose area under the 
curve (AUC0–120) during oral glucose tolerance test (r = −0.61, P = 0.009)
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reduction in calf vascular resistance was the strongest 
independent predictor of improvement in exogenous 
insulin clearance, whilst improvements in endothelial 
function (quantified as the finger reactive hyperaemic 
response) and glucose tolerance predicted improvement 
in endogenous insulin clearance. Third, that the sympa-
thoinhibition attained following HCD was modulated by 
baseline insulin status and did not correlate directly with 
changes in insulin clearance.
Relatively few studies to date have examined the effects 
of caloric restriction on insulin clearance in obese adults 
and these have pertained to changes in endogenous, but 
not exogenous insulin clearance [3, 15, 37, 38]. Bosello 
et  al. reported an average increase of 63  % in fasting 
C-peptide to insulin ratio after 3-weeks of a very low cal-
orie diet (VLCD, 320 kcal/day) which resulted in a 6.3 % 
body weight loss [37]. Polonsky et  al. studied changes 
in 24-h endogenous insulin clearance in different meta-
bolic sub-groups following a VLCD (600  kcal/day) over 
a 6-week period [38]. Weight loss of 16–19  % in body 
weight translated to improvements of 30–50 % in insulin 
clearance, with greatest benefits in type 2 diabetic sub-
jects. In another study 9.8  % weight loss over 9  weeks 
increased endogenous insulin clearance in response 
to graded glucose infusion by 42  % [3]. In our study, 
improvement in endogenous insulin clearance averaged 
17 % which is smaller in magnitude than the aforemen-
tioned studies. It is likely that these differences may be 
explained by the more moderate caloric restriction and 
longer intervention period utilized in our study. Both the 
level of negative energy balance and weight loss per se are 
known to influence changes in insulin sensitivity, meta-
bolic and autonomic parameters [39, 40].
The salient finding of our study is that improvement 
in vascular parameters (reduction in calf vascular resist-
ance and increase in finger reactive hyperaemic index), 
independent of weight changes, delineated those subjects 
who gained a benefit in insulin clearance following HCD 
from those who did not. Moreover, this relationship was 
bidirectional as enhanced insulin clearance post weight 
loss independently predicted reduction in calf vascular 
resistance. These data concur with previously published 
studies showing that hypertension is associated with 
decreased insulin clearance [10, 12] and that administra-
tion of the α1-adrenergic agonist phenylephrine during 
hyperinsulinemic euglycemic clamp acutely diminishes 
insulin clearance in healthy volunteers [19]. Changes in 
peripheral vascular tone may impact on insulin clear-
ance directly or indirectly via effects on insulin sensitiv-
ity. Impaired transcapillary transport of insulin caused by 
either decreased blood flow or permeability, or decreased 
capacity to vasodilate, could hinder the efflux of insulin 
from the intravascular space, hence decreasing insu-
lin clearance [10, 20, 41], as well as impacting on insu-
lin action [41, 42]. Our findings support the notion that 
insulin clearance and sensitivity are closely aligned [5–7] 
as improvement in Matsuda ISI and clamp derived glu-
cose utilization post weight loss were positively associ-
ated with both measures of insulin clearance, and suggest 
that vascular function may be a common pathophysi-
ological mediator of this association.
Our data underscore the potential importance of 
endothelial function in relation to insulin clearance at 
both the microvascular level and in skeletal muscle vas-
culature. Post ischemic finger reactive hyperaemia is 
a complex response, reflecting changes in digital blood 
Table 3 Stepwise regression analyses of changes in key study parameters in the HCD group (n = 17)
Regression analyses were adjusted for age (years) and change in body weight (kg). β is the power of the test performed with α = 0.05
Dependent variables Step Predictor variables Std.coeff r2 P β
Insulin clearance
 Δ Whole-body insulin clearance (mL m2 min−1) 1 Δ Calf vascular resistance (units) −0.53 0.40 0.01 0.94
2 Δ HDL-cholesterol (mmol/L) 0.40 0.55 0.05
 Δ Fasting C-peptide to insulin ratio 1 Δ Glucose AUC0-120 (mmol/L/min) −0.63 0.38 0.002 0.98
2 Δ Finger reactive hyperaemic index 0.51 0.64 0.006
Vascular
 Δ Fasting calf vascular resistance (units) 1 Δ Insulin clearance (mL m2 min−1) −0.55 0.40 0.01 0.95
2 Δ Log high sensitivity CRP (mg/mL) 0.40 0.55 0.047
 Δ Calf vascular resistance  
during OGTT (AUC0–120) (units)
1 Δ Fasting C-peptide (pmol/L) 0.63 0.48 <0.001 0.99
2 Δ M/I (mg kg FFM min−1 mU/L × 100) −0.47 0.69 0.008
 Δ Finger reactive hyperaemic index 1 Δ Mean arterial pressure (mmHg) −0.57 0.33 0.02 0.69
 Δ Mean arterial pressure (mmHg) 1 Δ Log arterial norepinephrine (pg/mL) 0.53 0.28 0.03 0.59
 Δ MSNA (bursts/100hb) 1 Δ Cardiac baroreflex sensitivity (ms/mmHg) −0.71 0.36 0.005 0.92
2 Δ Body weight (kg) −0.51 0.61 0.03
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flow and digital microvessel dilation, processes that 
depend on nitric oxide synthesis [35, 43]. Similarly, the 
vasodilatory response to endogenous insulin in skel-
etal muscle vasculature during OGTT is mediated by 
insulin-stimulated production of nitric oxide [44]. In 
our study, post weight loss improvement in these vas-
cular parameters related to enhanced insulin clear-
ance and insulin sensitivity and reduction in MAP and 
inflammatory milieu (plasma hs-CRP concentration). 
Other factors that may have contributed to improve-
ment in endothelial parameters include weight loss and/
or DASH diet induced changes in lipid profile (reduced 
plasma triglyceride and LDL-cholesterol and increased 
HDL-cholesterol concentrations) and reduction in gly-
cemia [29, 45, 46]. Enhanced plasma nitrite level in 
response to reactive hyperaemia, has been reported in 
obese hypertensive subjects after 2-week consumption 
of a DASH eating plan, and suggest an upregulation of 
nitric oxide bioavailability [47]. Our finding of enhanced 
vasodilatory response to OGTT following HCD is rel-
evant to postprandial glucose disposal and cardiovas-
cular risk and concurs with other published data [48]. 
It is notable that the Insulin Resistance Atherosclerosis 
Study, which followed 748 non-diabetic participants 
over 5-years to examine prospective changes in insulin 
clearance, observed that higher systolic blood pressure, 
plasma triglycerides and waist circumference at base-
line were associated with future decline of insulin clear-
ance, whereas higher HDL-cholesterol level predicted 
an increase in insulin clearance [12]. These findings 
likely reflect the convergence of metabolic syndrome 
components and insulin resistance on endothelial func-
tion and support our findings regarding the benefits of 
weight loss. It merits emphasis, that vascular responses 
to weight loss were variable within our cohort. One 
explanation for this is that baseline differences in insu-
lin status influenced the degree of sympathoinhibition 
attained independent of weight change. Insulin status 
has also been shown to affect the benefits of weight loss 
on flow-mediated vasodilation with favourable changes 
being manifest only in hyperinsulinemic individuals [36].
SNS activation promotes vasoconstriction, vascular 
structural changes, impaired endothelial function and 
capillary rarefaction and has been linked to the develop-
ment of insulin resistance in both prospective popula-
tion [49] and human experimental studies [21]. The level 
of sympathoinhibition attained in the present study was 
smaller than what we have previously reported in other 
cohorts with similar weight loss [50], and correlated with 
improvements in MAP, but not insulin clearance. Our 
subgroup analysis highlights that change in plasma insu-
lin levels is a key determinant of the sympathoinhibitory 
response following weight loss [26].
The strengths of our study are the detailed characteriza-
tion of study participants and the use of gold standard meth-
odology to evaluate insulin sensitivity and clearance and 
SNS activity. The limitations of our study include the rela-
tively small sample size and non-randomized study design. 
Also our study does not differentiate between the effects of 
negative energy balance and weight loss per se. Finally, the 
role of other unmeasured factors, for instance adiponectin, 
which may have impacted on endothelial function and insu-
lin clearance, merits further investigation [51].
Conclusions
Our study demonstrates a bidirectional inter-relation-
ship between changes in insulin clearance and vascular 
endothelial function during the course of a weight loss 
program. Improvement in risk factors associated with the 
metabolic syndrome, namely insulin resistance, hyper-
glycemia, proinflammatory state, blood pressure and 
HDL-cholesterol may underlie the vascular benefit and 
enhancement in insulin clearance.
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